Journal of Clinical Endocrinology & Metabolism, Vol 76, 1019-1024, Copyright © 1993 by Endocrine Society

ARTICLES

Oral gossypol in the treatment of metastatic adrenal cancer

MR Flack, RG Pyle, NM Mullen, B Lorenzo, YW Wu, RA Knazek, BC Nisula and MM Reidenberg
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.

Medical treatment of metastatic adrenal cancer is largely unsuccessful and has considerable toxicity. We previously demonstrated the activity of the plant toxin gossypol against human adrenal cancers in nude mice. We therefore examined the efficacy and toxicity of oral gossypol as a treatment for adrenal cancer in humans. Twenty-one patients with metastatic adrenal cancer received oral gossypol at doses of 30-70 mg/day. Patients were monitored for side effects of gossypol, changes in hormone secretion, and tumor response. Eighteen patients completed at least 6 weeks of gossypol treatment. Three of these patients, whose tumors were refractory to other chemotherapeutic agents, had partial tumor responses (> or = 50% decrease in tumor volume) that lasted from several months to over 1 yr. One patient had a minor response followed by resection of her remaining disease, 1 patient had stable disease, and 13 patients had disease progression. Three patients died of their disease without receiving sufficient gossypol to achieve detectable drug levels, and were eliminated from the final analysis. The side effects of gossypol were generally well tolerated; the only serious side effect was abdominal ileus that resolved when the drug was temporarily withheld and restarted at a lower dose. We conclude that oral gossypol can be used relatively safely on an outpatient basis for the treatment of metastatic adrenal cancer. The response rate is similar to the other agents currently available for adrenal cancer, and responses were seen in patients who had failed other chemotherapeutic regimens. This study provides the first indication that gossypol may have activity against cancer in humans, suggesting the need for further investigation of gossypol as an antitumor agent.

This article has been cited by other articles:

				Y.-W. HUANG, L.-S. WANG, M. K. DOWD, P. J. WAN, and Y. C. LIN (-)-Gossypol Reduces Invasiveness in Metastatic Prostate Cancer Cells Anticancer Res, June 1, 2009; 29(6): 2179 - 2188. [Abstract] [Full Text] [PDF]

				L. M. Krug and M. C. Pietanza Emerging Therapies in Small Cell Lung Cancer ASCO Educational Book, January 1, 2009; 2009(1): 455 - 460. [Abstract] [Full Text] [PDF]

				B. D. Zeitlin, I. J. Zeitlin, and J. E. Nor Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents J. Clin. Oncol., September 1, 2008; 26(25): 4180 - 4188. [Abstract] [Full Text] [PDF]

				L. Paoluzzi, M. Gonen, J. R. Gardner, J. Mastrella, D. Yang, J. Holmlund, M. Sorensen, L. Leopold, K. Manova, G. Marcucci, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma Blood, June 1, 2008; 111(11): 5350 - 5358. [Abstract] [Full Text] [PDF]

				R. M. Mohammad, A. S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, G. Wang, Z. Nikolovska-Coleska, S. Wang, and A. Al-Katib Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1 Clin. Cancer Res., April 1, 2007; 13(7): 2226 - 2235. [Abstract] [Full Text] [PDF]

				L. S. Kirschner Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21. [Abstract] [Full Text] [PDF]

				G. W. Mayr, S. Windhorst, and K. Hillemeier Antiproliferative Plant and Synthetic Polyphenolics Are Specific Inhibitors of Vertebrate Inositol-1,4,5-trisphosphate 3-Kinases and Inositol Polyphosphate Multikinase J. Biol. Chem., April 8, 2005; 280(14): 13229 - 13240. [Abstract] [Full Text] [PDF]

				R. M. Mohammad, S. Wang, A. Aboukameel, B. Chen, X. Wu, J. Chen, and A. Al-Katib Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(-)-gossypol] against diffuse large cell lymphoma Mol. Cancer Ther., January 1, 2005; 4(1): 13 - 21. [Abstract] [Full Text] [PDF]

				C. L. Oliver, J. A. Bauer, K. G. Wolter, M. L. Ubell, A. Narayan, K. M. O'Connell, S. G. Fisher, S. Wang, X. Wu, M. Ji, et al. In vitro Effects of the BH3 Mimetic, (-)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells Clin. Cancer Res., November 15, 2004; 10(22): 7757 - 7763. [Abstract] [Full Text] [PDF]

				J. Qiu, L. R. Levin, J. Buck, and M. M. Reidenberg Different Pathways of Cell Killing by Gossypol Enantiomers Experimental Biology and Medicine, June 1, 2002; 227(6): 398 - 401. [Abstract] [Full Text] [PDF]

				R. Baumgrass, M. Weiwad, F. Erdmann, J. O. Liu, D. Wunderlich, S. Grabley, and G. Fischer Reversible Inhibition of Calcineurin by the Polyphenolic Aldehyde Gossypol J. Biol. Chem., December 14, 2001; 276(51): 47914 - 47921. [Abstract] [Full Text] [PDF]

				A. C. Latronico and G. P. Chrousos Adrenocortical Tumors J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1317 - 1324. [Full Text] [PDF]